🟢 Taysha Gene Therapies is trading 7.54% up in pre-market

Taysha Gene Therapies is trading at $3.85, up 7.54% in pre-market, with no clear company-specific catalyst identified.

• The company’s latest listed releases were dated October 2 and October 1, not October 14.
• A Rett syndrome clinical-program presentation is scheduled at the Child Neurology Society meeting October 14–17, but available information does not establish it as the cause of the move.
• Major indexes are modestly higher, not enough to establish a broad-market catalyst.